Akero Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $284 |
Gross Profit | -1 | -1 | 282 | |
EBITDA | -71,458 | -54,755 | -52,352 | -54,287 |
EBIT | -71,459 | -54,756 | -52,353 | -54,289 |
Net Income | -72,705 | -55,987 | -53,344 | -55,186 |
Net Change In Cash | 0 | 0 | 0 | 284 |
Free Cash Flow | -70,424 | -57,453 | -35,140 | -48,627 |
Cash | 316,065 | 310,355 | 623,854 | 234,207 |
Basic Shares | 69,442 | 69,160 | 59,307 | 55,717 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -29 | -260 | -100,886 | -80,154 |
EBITDA | -148,631 | -111,034 | -100,845 | -80,137 |
EBIT | -148,660 | -111,294 | -100,886 | -80,154 |
Net Income | -151,759 | -108,910 | -100,736 | -79,190 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 99,290 | -36,799 | 122,542 | |
Free Cash Flow | -145,367 | -92,517 | -79,681 | -70,952 |
Cash | 234,207 | 249,773 | 150,483 | 187,242 |
Basic Shares | 52,568 | 38,984 | 34,827 | 31,463 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.05 |
2024-06-30 | -$0.81 |
2024-03-31 | -$0.90 |
2023-12-31 | -$0.99 |
